Johnson, Peter W.M.
Johnson, P. W. M.
Peter Johnson British oncologist
VIAF ID: 221557525 (Personal)
Permalink: http://viaf.org/viaf/221557525
Preferred Forms
- 200 _ | ‡a Johnson ‡b Peter W. M.
-
- 100 1 _ ‡a Johnson, P. W. M.
- 100 1 _ ‡a Johnson, Peter W. M.
- 100 1 _ ‡a Johnson, Peter W.M.
-
-
- 100 0 _ ‡a Peter Johnson ‡c British oncologist
4xx's: Alternate Name Forms (4)
Works
Title | Sources |
---|---|
[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. | |
Bone marrow and peripheral blood stem cell transplantation for malignancy, 1998: | |
Comparison of Outcomes in Studies of Advanced Hodgkin's Lymphoma | |
Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. | |
Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies. | |
Defects in lymphocyte subsets and serological memory persist a median of 10 years after high-dose therapy and autologous progenitor cell rescue for malignant lymphoma. | |
Development, validation and application of ELISAs for pharmacokinetic and HACA assessment of a chimeric anti-CD40 monoclonal antibody in human serum. | |
Differential impact of CD27 and 4-1BB costimulation on effector and memory CD8 T cell generation following peptide immunization. | |
Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit | |
Distinct promoters mediate constitutive and inducible Bcl-XL expression in malignant lymphocytes. | |
DNA vaccines to attack cancer | |
The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia | |
Enumeration and phenotypic assessment of human plasmacytoid and myeloid dendritic cells in whole blood | |
Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation | |
Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma | |
Ex vivo assays of dendritic cell activation and cytokine profiles as predictors of in vivo effects in an anti-human CD40 monoclonal antibody ChiLob 7/4 phase I trial | |
Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. | |
Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization. | |
FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs. | |
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. | |
Focal skeletal FDG uptake indicates poor prognosis in cHL regardless of extent and first-line chemotherapy | |
Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study | |
Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group. | |
Genome-wide promoter methylation of hairy cell leukemia | |
Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins | |
Hepatitis C virus and GBV-C virus prevalence among patients with B-cell lymphoma in different European regions: a case-control study of the International Extranodal Lymphoma Study Group. | |
Ibrutinib therapy releases leukemic surface IgM from antigen drive in chronic lymphocytic leukemia patients | |
Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function | |
Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling. | |
Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers | |
Intestinal strictures: a new complication of treatment for primary gastrointestinal diffuse large B-cell lymphoma | |
Lectin binding to surface Ig variable regions provides a universal persistent activating signal for follicular lymphoma cells. | |
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results | |
Low-dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue. | |
Lymphoma, c2005: | |
Lymphoma methods and protocols | |
Lymphoma: turning biology into cures | |
Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma | |
Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. | |
Microscopic Intratumoral Dosimetry of Radiolabeled Antibodies Is a Critical Determinant of Successful Radioimmunotherapy in B-Cell Lymphoma | |
Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy | |
Mutation screening using formalin-fixed paraffin-embedded tissues: a stratified approach according to DNA quality | |
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study | |
Novel antibodies targeting immune regulatory checkpoints for cancer therapy. | |
The nuclear BAG-1 isoform, BAG-1L, enhances oestrogen-dependent transcription. | |
Optimising anti-tumour CD8 T-cell responses using combinations of immunomodulatory antibodies. | |
Optimizing therapy in advanced-stage Hodgkin lymphoma. | |
Outcome of Elderly Patients with Diffuse Large B-cell Lymphoma Treated with R-CHOP: Results from the UK NCRI R-CHOP14v21 trial with combined analysis of molecular characteristics with the DSHNHL RICOVER-60 trial | |
Pharmacological inhibitors of NF-κB accelerate apoptosis in chronic lymphocytic leukaemia cells | |
Phase 1/2 study of fractionated 131I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy | |
Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1 | |
Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies. | |
Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks | |
Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma | |
The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model | |
Population-based demographic study of karyotypes in 1709 patients with adult acute myeloid leukemia | |
Positive and negative selection to reduce tumour contamination in peripheral blood stem cell harvests. | |
Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study | |
Prediction of single-nucleotide substitutions that result in exon skipping: identification of a splicing silencer in BRCA1 exon 6. | |
The prognosis of MYC translocation positive diffuse large B-cell lymphoma depends on the second hit. | |
Prognostic models for primary mediastinal | |
Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. | |
Resources-Stratified Guidelines for Classical Hodgkin Lymphoma | |
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. | |
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles | |
RIVA - a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial | |
The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survival | |
S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. | |
Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab | |
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: A systematic review and meta-analysis of randomized clinical trials. | |
Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. | |
Short peptides derived from the BAG-1 C-terminus inhibit the interaction between BAG-1 and HSC70 and decrease breast cancer cell growth | |
Stratified medicine for cancer therapy. | |
Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL. | |
T-cell non-Hodgkin's lymphoma: treatment outcomes and survival in 3 large UK centres | |
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma | |
Thioflavin S (NSC71948) interferes with Bcl-2-associated athanogene (BAG-1)-mediated protein-protein interactions. | |
Transmission of diffuse large B-cell lymphoma by an allogeneic stem-cell transplant | |
Universal N-glycosylation sites introduced into the B-cell receptor of follicular lymphoma by somatic mutation: a second tumorigenic event? | |
Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment | |
Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling | |
Variable Responses of MYC Translocation Positive Lymphoma Cell Lines To Different Combinations of Novel Agents: Impact of BCL2 Family Protein Expression. | |
Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia | |
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extran | |
Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? |